Amgen stock fell 1.04 percent as Q2 revenue beat estimates

Published on 10/03/2026 at 23:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock stood at USD 403.04 on October 2, 2026, 9.8 percent below its 52-week high. Q2 revenue reached USD 10.05 billion versus USD 9.43 billion consensus.

Pop-Art-Comic-Illustration eines Wissenschaftlers mit Spritze und Fläschchen vor buntem Halbton-Punktmuster — Amgen Inc. (ISIN US0311621009) präsentiert sich hier als farbenfrohe Pop-Art-Comic-Szene mit forschendem Laborwissenschaftler, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) closed at USD 403.04 on Nasdaq on October 2, 2026, down 1.04 percent from the prior session. The move came as investors weighed a strong second-quarter revenue result against the biotechnology group's elevated valuation and pipeline execution demands.

Revenue beats consensus

Amgen reported second-quarter 2026 revenue of USD 10.05 billion versus consensus of USD 9.43 billion, while quarterly revenue increased 9.5 percent year over year, according to MarketBeat. The comparison gives Amgen a quantified growth signal even as the share price remains below its annual peak.

The same report said Amgen set fiscal 2026 EPS guidance at USD 22.300-23.500. That guidance provides a reference point for the market's 2026 earnings expectations, while the Q2 revenue result shows that commercial growth is already contributing to the investment case.

Pipeline adds another growth lever

Amgen's investor materials list positive topline phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease, announced September 22, 2026, alongside recent progress for IMDELLTRA. The company also presented its portfolio and pipeline at healthcare conferences in September, according to Amgen.

At the Wells Fargo healthcare conference on September 10, 2026, Amgen described six key growth drivers that expanded 26 percent year over year and represented 70 percent of second-quarter product sales, according to Investing.com. Management also guided to a 45 percent to 46 percent non-GAAP operating margin for the year, framing the central tradeoff as continued research investment alongside profitability.

Stock remains below yearly high

Amgen's October 2 closing price was 9.8 percent below the 52-week high of USD 447.03 and USD 115.04 above the 52-week low of USD 288.00. The session volume reached 3,502,867 shares, while market capitalization stood at USD 217.5 billion as of October 2, 2026.

For investors, the central read-through is numerical: quarterly revenue exceeded consensus by USD 620 million, but the stock still lost 1.04 percent in the latest completed session. That combination places execution, margin discipline and late-stage pipeline delivery at the center of the Amgen stock story.